#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=7 .
1-1	0-1	7	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Involvement of the Apelin System in the Pathogenesis of Liver Fibrosis
2-1	4-15	Involvement	abstract[2]	new[2]	_	_
2-2	16-18	of	abstract[2]	new[2]	_	_
2-3	19-22	the	abstract[2]|abstract[4]	new[2]|new[4]	coref	3-1[9_4]
2-4	23-29	Apelin	abstract[2]|organization|abstract[4]	new[2]|new|new[4]	coref	3-2
2-5	30-36	System	abstract[2]|abstract[4]	new[2]|new[4]	_	_
2-6	37-39	in	abstract[2]|abstract[4]	new[2]|new[4]	_	_
2-7	40-43	the	abstract[2]|abstract[4]|abstract[5]	new[2]|new[4]|new[5]	_	_
2-8	44-56	Pathogenesis	abstract[2]|abstract[4]|abstract[5]	new[2]|new[4]|new[5]	_	_
2-9	57-59	of	abstract[2]|abstract[4]|abstract[5]	new[2]|new[4]|new[5]	_	_
2-10	60-65	Liver	abstract[2]|abstract[4]|abstract[5]|object	new[2]|new[4]|new[5]|new	coref	6-16
2-11	66-74	Fibrosis	abstract[2]|abstract[4]|abstract[5]|abstract	new[2]|new[4]|new[5]|new	coref	4-12[19_0]

#Text=The apelin system has certain therapeutic abilities , but it may also play a role in disease depending on the cellular and molecular milieu .
3-1	75-78	The	abstract[9]	giv[9]	ana	3-10[0_9]
3-2	79-85	apelin	organization|abstract[9]	giv|giv[9]	coref	4-10[17_0]
3-3	86-92	system	abstract[9]	giv[9]	_	_
3-4	93-96	has	_	_	_	_
3-5	97-104	certain	abstract[10]	new[10]	_	_
3-6	105-116	therapeutic	abstract[10]	new[10]	_	_
3-7	117-126	abilities	abstract[10]	new[10]	_	_
3-8	127-128	,	_	_	_	_
3-9	129-132	but	_	_	_	_
3-10	133-135	it	abstract	giv	coref	6-9[33_0]
3-11	136-139	may	_	_	_	_
3-12	140-144	also	_	_	_	_
3-13	145-149	play	_	_	_	_
3-14	150-151	a	abstract[12]	new[12]	coref	6-7[31_12]
3-15	152-156	role	abstract[12]	new[12]	_	_
3-16	157-159	in	abstract[12]	new[12]	_	_
3-17	160-167	disease	abstract[12]|abstract	new[12]|new	coref	6-16[35_0]
3-18	168-177	depending	_	_	_	_
3-19	178-180	on	_	_	_	_
3-20	181-184	the	quantity[14]	new[14]	_	_
3-21	185-193	cellular	quantity[14]	new[14]	_	_
3-22	194-197	and	quantity[14]	new[14]	_	_
3-23	198-207	molecular	quantity[14]	new[14]	_	_
3-24	208-214	milieu	quantity[14]	new[14]	_	_
3-25	215-216	.	_	_	_	_

#Text=A clear example of this is the role of apelin in tissue fibrosis .
4-1	217-218	A	abstract[15]	new[15]	coref	4-7[16_15]
4-2	219-224	clear	abstract[15]	new[15]	_	_
4-3	225-232	example	abstract[15]	new[15]	_	_
4-4	233-235	of	abstract[15]	new[15]	_	_
4-5	236-240	this	abstract[15]	new[15]	_	_
4-6	241-243	is	_	_	_	_
4-7	244-247	the	abstract[16]	giv[16]	_	_
4-8	248-252	role	abstract[16]	giv[16]	_	_
4-9	253-255	of	abstract[16]	giv[16]	_	_
4-10	256-262	apelin	abstract[16]|organization[17]	giv[16]|giv[17]	coref	5-1[0_17]
4-11	263-265	in	abstract[16]|organization[17]	giv[16]|giv[17]	_	_
4-12	266-272	tissue	abstract[16]|organization[17]|object|abstract[19]	giv[16]|giv[17]|new|giv[19]	coref|coref	5-10[25_19]|5-10[25_19]
4-13	273-281	fibrosis	abstract[16]|organization[17]|abstract[19]	giv[16]|giv[17]|giv[19]	_	_
4-14	282-283	.	_	_	_	_

#Text=Apelin displays anti-fibrotic actions counteracting AII in models of cardiac fibrosis and renal fibrosis .
5-1	284-290	Apelin	substance	giv	coref	6-10
5-2	291-299	displays	_	_	_	_
5-3	300-313	anti-fibrotic	abstract[21]	new[21]	_	_
5-4	314-321	actions	abstract[21]	new[21]	_	_
5-5	322-335	counteracting	_	_	_	_
5-6	336-339	AII	abstract	new	coref	7-19
5-7	340-342	in	_	_	_	_
5-8	343-349	models	abstract[23]	new[23]	_	_
5-9	350-352	of	abstract[23]	new[23]	_	_
5-10	353-360	cardiac	abstract[23]|person|abstract[25]	new[23]|new|giv[25]	coref|coref	5-13[27_25]|5-13[27_25]
5-11	361-369	fibrosis	abstract[23]|abstract[25]	new[23]|giv[25]	_	_
5-12	370-373	and	abstract[23]	new[23]	_	_
5-13	374-379	renal	abstract[23]|abstract|abstract[27]	new[23]|new|giv[27]	coref|coref	7-29[45_27]|7-29[45_27]
5-14	380-388	fibrosis	abstract[23]|abstract[27]	new[23]|giv[27]	_	_
5-15	389-390	.	_	_	_	_

#Text=In contrast , the scenario and role of the apelin system are completely different in liver disease .
6-1	391-393	In	_	_	_	_
6-2	394-402	contrast	abstract	new	_	_
6-3	403-404	,	_	_	_	_
6-4	405-408	the	abstract[29]|abstract[30]	new[29]|new[30]	ana|ana	7-12[38_30]|7-12[38_30]
6-5	409-417	scenario	abstract[29]|abstract[30]	new[29]|new[30]	_	_
6-6	418-421	and	abstract[30]	new[30]	_	_
6-7	422-426	role	abstract[30]|abstract[31]	new[30]|giv[31]	_	_
6-8	427-429	of	abstract[30]|abstract[31]	new[30]|giv[31]	_	_
6-9	430-433	the	abstract[30]|abstract[31]|abstract[33]	new[30]|giv[31]|giv[33]	_	_
6-10	434-440	apelin	abstract[30]|abstract[31]|organization|abstract[33]	new[30]|giv[31]|giv|giv[33]	coref	7-1
6-11	441-447	system	abstract[30]|abstract[31]|abstract[33]	new[30]|giv[31]|giv[33]	_	_
6-12	448-451	are	_	_	_	_
6-13	452-462	completely	_	_	_	_
6-14	463-472	different	_	_	_	_
6-15	473-475	in	_	_	_	_
6-16	476-481	liver	object|abstract[35]	giv|giv[35]	coref|coref|coref|coref	7-29|12-27[91_35]|7-29|12-27[91_35]
6-17	482-489	disease	abstract[35]	giv[35]	_	_
6-18	490-491	.	_	_	_	_

#Text=Apelin is a hepatic pro-fibrotic agent , in part by mediating some of the fibrogenic effects triggered by AII and ET-1 in the activation of HSC occurring in liver fibrosis .
7-1	492-498	Apelin	person	giv	coref	7-3[37_0]
7-2	499-501	is	_	_	_	_
7-3	502-503	a	person[37]	giv[37]	coref	8-24[0_37]
7-4	504-511	hepatic	person[37]	giv[37]	_	_
7-5	512-524	pro-fibrotic	person[37]	giv[37]	_	_
7-6	525-530	agent	person[37]	giv[37]	_	_
7-7	531-532	,	person[37]	giv[37]	_	_
7-8	533-535	in	person[37]	giv[37]	_	_
7-9	536-540	part	person[37]	giv[37]	_	_
7-10	541-543	by	_	_	_	_
7-11	544-553	mediating	_	_	_	_
7-12	554-558	some	abstract[38]	giv[38]	_	_
7-13	559-561	of	abstract[38]	giv[38]	_	_
7-14	562-565	the	abstract[38]|abstract[39]	giv[38]|new[39]	_	_
7-15	566-576	fibrogenic	abstract[38]|abstract[39]	giv[38]|new[39]	_	_
7-16	577-584	effects	abstract[38]|abstract[39]	giv[38]|new[39]	_	_
7-17	585-594	triggered	_	_	_	_
7-18	595-597	by	_	_	_	_
7-19	598-601	AII	abstract	giv	coref	27-10
7-20	602-605	and	_	_	_	_
7-21	606-610	ET-1	abstract	new	_	_
7-22	611-613	in	_	_	_	_
7-23	614-617	the	event[42]	new[42]	coref	11-17[80_42]
7-24	618-628	activation	event[42]	new[42]	_	_
7-25	629-631	of	event[42]	new[42]	_	_
7-26	632-635	HSC	event[42]|substance	new[42]|new	coref	10-19
7-27	636-645	occurring	_	_	_	_
7-28	646-648	in	_	_	_	_
7-29	649-654	liver	object|abstract[45]	giv|giv[45]	coref|coref|coref|coref	8-11|9-13[60_45]|8-11|9-13[60_45]
7-30	655-663	fibrosis	abstract[45]	giv[45]	_	_
7-31	664-665	.	_	_	_	_

#Text=These outcomes highlight the intriguing difference between myofibroblastic-cell types in liver compared to myofibroblasts in heart , kidney , or skin in which apelin acts by decreasing myofibroblast accumulation and activity .
8-1	666-671	These	abstract[46]	new[46]	_	_
8-2	672-680	outcomes	abstract[46]	new[46]	_	_
8-3	681-690	highlight	_	_	_	_
8-4	691-694	the	abstract[47]	new[47]	_	_
8-5	695-705	intriguing	abstract[47]	new[47]	_	_
8-6	706-716	difference	abstract[47]	new[47]	_	_
8-7	717-724	between	abstract[47]	new[47]	_	_
8-8	725-745	myofibroblastic-cell	abstract[47]|place[48]	new[47]|new[48]	_	_
8-9	746-751	types	abstract[47]|place[48]	new[47]|new[48]	_	_
8-10	752-754	in	abstract[47]|place[48]	new[47]|new[48]	_	_
8-11	755-760	liver	abstract[47]|place[48]|object	new[47]|new[48]|giv	coref	9-13
8-12	761-769	compared	_	_	_	_
8-13	770-772	to	_	_	_	_
8-14	773-787	myofibroblasts	abstract[50]	new[50]	_	_
8-15	788-790	in	abstract[50]	new[50]	_	_
8-16	791-796	heart	abstract[50]|place	new[50]|new	_	_
8-17	797-798	,	abstract[50]	new[50]	_	_
8-18	799-805	kidney	abstract[50]|place	new[50]|new	_	_
8-19	806-807	,	abstract[50]	new[50]	_	_
8-20	808-810	or	abstract[50]	new[50]	_	_
8-21	811-815	skin	abstract[50]|object	new[50]|new	_	_
8-22	816-818	in	_	_	_	_
8-23	819-824	which	_	_	_	_
8-24	825-831	apelin	organization	giv	coref	9-4
8-25	832-836	acts	_	_	_	_
8-26	837-839	by	_	_	_	_
8-27	840-850	decreasing	_	_	_	_
8-28	851-864	myofibroblast	abstract[55]	new[55]	_	_
8-29	865-877	accumulation	abstract[55]	new[55]	_	_
8-30	878-881	and	_	_	_	_
8-31	882-890	activity	abstract	new	_	_
8-32	891-892	.	_	_	_	_

#Text=In vitro , apelin has also demonstrated a significant potential to promote liver fibrosis .
9-1	893-895	In	_	_	_	_
9-2	896-901	vitro	_	_	_	_
9-3	902-903	,	_	_	_	_
9-4	904-910	apelin	organization	giv	coref	12-3
9-5	911-914	has	_	_	_	_
9-6	915-919	also	_	_	_	_
9-7	920-932	demonstrated	_	_	_	_
9-8	933-934	a	abstract[58]	new[58]	_	_
9-9	935-946	significant	abstract[58]	new[58]	_	_
9-10	947-956	potential	abstract[58]	new[58]	_	_
9-11	957-959	to	_	_	_	_
9-12	960-967	promote	_	_	_	_
9-13	968-973	liver	object|abstract[60]	giv|giv[60]	ana|coref|ana|coref	10-1[0_60]|12-24|10-1[0_60]|12-24
9-14	974-982	fibrosis	abstract[60]	giv[60]	_	_
9-15	983-984	.	_	_	_	_

#Text=It acts directly on LX-2 cells ( a cell line used as a reliable in vitro model of HSC ) through Erk signalling , stimulating cell survival and the synthesis of PDGF-Î² receptor and collagen-I in these cells .
10-1	985-987	It	abstract	giv	coref	12-24[89_0]
10-2	988-992	acts	_	_	_	_
10-3	993-1001	directly	_	_	_	_
10-4	1002-1004	on	_	_	_	_
10-5	1005-1009	LX-2	substance|object[63]	new|new[63]	appos|coref|appos|coref	10-8[64_63]|19-48|10-8[64_63]|19-48
10-6	1010-1015	cells	object[63]	new[63]	_	_
10-7	1016-1017	(	_	_	_	_
10-8	1018-1019	a	object[64]	giv[64]	coref	10-37[74_64]
10-9	1020-1024	cell	object[64]	giv[64]	_	_
10-10	1025-1029	line	object[64]	giv[64]	_	_
10-11	1030-1034	used	_	_	_	_
10-12	1035-1037	as	_	_	_	_
10-13	1038-1039	a	_	_	_	_
10-14	1040-1048	reliable	_	_	_	_
10-15	1049-1051	in	_	_	_	_
10-16	1052-1057	vitro	abstract[65]	new[65]	_	_
10-17	1058-1063	model	abstract[65]	new[65]	_	_
10-18	1064-1066	of	abstract[65]	new[65]	_	_
10-19	1067-1070	HSC	abstract[65]|abstract	new[65]|giv	coref	12-10
10-20	1071-1072	)	_	_	_	_
10-21	1073-1080	through	_	_	_	_
10-22	1081-1084	Erk	person	new	_	_
10-23	1085-1095	signalling	_	_	_	_
10-24	1096-1097	,	_	_	_	_
10-25	1098-1109	stimulating	_	_	_	_
10-26	1110-1114	cell	place|event[69]	new|new[69]	_	_
10-27	1115-1123	survival	event[69]	new[69]	_	_
10-28	1124-1127	and	_	_	_	_
10-29	1128-1131	the	event[70]	new[70]	_	_
10-30	1132-1141	synthesis	event[70]	new[70]	_	_
10-31	1142-1144	of	event[70]	new[70]	_	_
10-32	1145-1151	PDGF-Î²	event[70]|abstract|object[72]	new[70]|new|new[72]	coref|coref	11-4|11-4
10-33	1152-1160	receptor	event[70]|object[72]	new[70]|new[72]	_	_
10-34	1161-1164	and	event[70]	new[70]	_	_
10-35	1165-1175	collagen-I	event[70]|substance[73]	new[70]|new[73]	_	_
10-36	1176-1178	in	event[70]|substance[73]	new[70]|new[73]	_	_
10-37	1179-1184	these	event[70]|substance[73]|object[74]	new[70]|new[73]|giv[74]	coref	19-48[140_74]
10-38	1185-1190	cells	event[70]|substance[73]|object[74]	new[70]|new[73]|giv[74]	_	_
10-39	1191-1192	.	_	_	_	_

#Text=In turn , PDGF-Î² and LPS can stimulate the expression of APJ , expanding and perpetuating HSC activation .
11-1	1193-1195	In	_	_	_	_
11-2	1196-1200	turn	abstract	new	_	_
11-3	1201-1202	,	_	_	_	_
11-4	1203-1209	PDGF-Î²	abstract	giv	coref	28-12
11-5	1210-1213	and	_	_	_	_
11-6	1214-1217	LPS	substance	new	_	_
11-7	1218-1221	can	_	_	_	_
11-8	1222-1231	stimulate	_	_	_	_
11-9	1232-1235	the	abstract[78]	new[78]	_	_
11-10	1236-1246	expression	abstract[78]	new[78]	_	_
11-11	1247-1249	of	abstract[78]	new[78]	_	_
11-12	1250-1253	APJ	abstract[78]|abstract	new[78]|new	coref	15-12
11-13	1254-1255	,	_	_	_	_
11-14	1256-1265	expanding	_	_	_	_
11-15	1266-1269	and	_	_	_	_
11-16	1270-1282	perpetuating	_	_	_	_
11-17	1283-1286	HSC	event[80]	giv[80]	_	_
11-18	1287-1297	activation	event[80]	giv[80]	_	_
11-19	1298-1299	.	_	_	_	_

#Text=Therefore , apelin may , in theory , induce HSC to a pro-fibrogenic profile and prolong its stimulation autocrinally during all stages of liver fibrosis in chronic liver disease (
12-1	1300-1309	Therefore	_	_	_	_
12-2	1310-1311	,	_	_	_	_
12-3	1312-1318	apelin	organization	giv	coref	17-5
12-4	1319-1322	may	_	_	_	_
12-5	1323-1324	,	_	_	_	_
12-6	1325-1327	in	_	_	_	_
12-7	1328-1334	theory	abstract	new	_	_
12-8	1335-1336	,	_	_	_	_
12-9	1337-1343	induce	_	_	_	_
12-10	1344-1347	HSC	substance	giv	ana	12-17
12-11	1348-1350	to	_	_	_	_
12-12	1351-1352	a	abstract[84]	new[84]	_	_
12-13	1353-1367	pro-fibrogenic	abstract[84]	new[84]	_	_
12-14	1368-1375	profile	abstract[84]	new[84]	_	_
12-15	1376-1379	and	_	_	_	_
12-16	1380-1387	prolong	_	_	_	_
12-17	1388-1391	its	substance|abstract[86]	giv|new[86]	coref|coref	20-8|20-8
12-18	1392-1403	stimulation	abstract[86]	new[86]	_	_
12-19	1404-1416	autocrinally	_	_	_	_
12-20	1417-1423	during	_	_	_	_
12-21	1424-1427	all	abstract[87]	new[87]	_	_
12-22	1428-1434	stages	abstract[87]	new[87]	_	_
12-23	1435-1437	of	abstract[87]	new[87]	_	_
12-24	1438-1443	liver	abstract[87]|object|abstract[89]	new[87]|giv|giv[89]	coref|coref|coref|coref	12-28|15-28[0_89]|12-28|15-28[0_89]
12-25	1444-1452	fibrosis	abstract[87]|abstract[89]	new[87]|giv[89]	_	_
12-26	1453-1455	in	abstract[87]|abstract[89]	new[87]|giv[89]	_	_
12-27	1456-1463	chronic	abstract[87]|abstract[89]|abstract[91]	new[87]|giv[89]|giv[91]	coref	19-43[138_91]
12-28	1464-1469	liver	abstract[87]|abstract[89]|object|abstract[91]	new[87]|giv[89]|giv|giv[91]	coref	19-44
12-29	1470-1477	disease	abstract[87]|abstract[89]|abstract[91]	new[87]|giv[89]|giv[91]	_	_
12-30	1478-1479	(	_	_	_	_

#Text=Figure 6
13-1	1480-1486	Figure	object[92]	new[92]	_	_
13-2	1487-1488	6	object[92]	new[92]	_	_

#Text=) .
14-1	1489-1490	)	_	_	_	_
14-2	1491-1492	.	_	_	_	_

#Text=In fact , some data have revealed that the inhibition of APJ using F13A ( an APJ antagonist ) prevents fibrosis progression in rats under a non-discontinued fibrosis induction program using CCl4 .
15-1	1493-1495	In	_	_	_	_
15-2	1496-1500	fact	_	_	_	_
15-3	1501-1502	,	_	_	_	_
15-4	1503-1507	some	abstract[93]	new[93]	coref	29-3[236_93]
15-5	1508-1512	data	abstract[93]	new[93]	_	_
15-6	1513-1517	have	_	_	_	_
15-7	1518-1526	revealed	_	_	_	_
15-8	1527-1531	that	_	_	_	_
15-9	1532-1535	the	event[94]	new[94]	coref	18-5[117_94]
15-10	1536-1546	inhibition	event[94]	new[94]	_	_
15-11	1547-1549	of	event[94]	new[94]	_	_
15-12	1550-1553	APJ	event[94]|abstract	new[94]|giv	coref	15-17
15-13	1554-1559	using	_	_	_	_
15-14	1560-1564	F13A	abstract	new	_	_
15-15	1565-1566	(	_	_	_	_
15-16	1567-1569	an	person[98]	new[98]	_	_
15-17	1570-1573	APJ	abstract|person[98]	giv|new[98]	coref	17-15[114_0]
15-18	1574-1584	antagonist	person[98]	new[98]	_	_
15-19	1585-1586	)	_	_	_	_
15-20	1587-1595	prevents	_	_	_	_
15-21	1596-1604	fibrosis	abstract[99]	new[99]	_	_
15-22	1605-1616	progression	abstract[99]	new[99]	_	_
15-23	1617-1619	in	abstract[99]	new[99]	_	_
15-24	1620-1624	rats	abstract[99]|animal[100]	new[99]|new[100]	coref	18-22[124_100]
15-25	1625-1630	under	abstract[99]|animal[100]	new[99]|new[100]	_	_
15-26	1631-1632	a	abstract[99]|animal[100]|abstract[103]	new[99]|new[100]|new[103]	_	_
15-27	1633-1649	non-discontinued	abstract[99]|animal[100]|abstract[103]	new[99]|new[100]|new[103]	_	_
15-28	1650-1658	fibrosis	abstract[99]|animal[100]|abstract|abstract[103]	new[99]|new[100]|giv|new[103]	coref	16-14
15-29	1659-1668	induction	abstract[99]|animal[100]|abstract|abstract[103]	new[99]|new[100]|new|new[103]	_	_
15-30	1669-1676	program	abstract[99]|animal[100]|abstract[103]	new[99]|new[100]|new[103]	_	_
15-31	1677-1682	using	_	_	_	_
15-32	1683-1687	CCl4	object	new	coref	21-22[156_0]
15-33	1688-1689	.	_	_	_	_

#Text=Several investigations have uncovered the close and integrated relationship between pathological angiogenesis and fibrosis .
16-1	1690-1697	Several	abstract[105]	new[105]	_	_
16-2	1698-1712	investigations	abstract[105]	new[105]	_	_
16-3	1713-1717	have	_	_	_	_
16-4	1718-1727	uncovered	_	_	_	_
16-5	1728-1731	the	abstract[106]	new[106]	coref	19-2[125_106]
16-6	1732-1737	close	abstract[106]	new[106]	_	_
16-7	1738-1741	and	abstract[106]	new[106]	_	_
16-8	1742-1752	integrated	abstract[106]	new[106]	_	_
16-9	1753-1765	relationship	abstract[106]	new[106]	_	_
16-10	1766-1773	between	abstract[106]	new[106]	_	_
16-11	1774-1786	pathological	abstract[106]|abstract[107]|abstract[108]	new[106]|new[107]|new[108]	coref|coref|coref|coref	18-13[0_107]|21-13[152_108]|18-13[0_107]|21-13[152_108]
16-12	1787-1799	angiogenesis	abstract[106]|abstract[107]|abstract[108]	new[106]|new[107]|new[108]	_	_
16-13	1800-1803	and	abstract[106]|abstract[108]	new[106]|new[108]	_	_
16-14	1804-1812	fibrosis	abstract[106]|abstract[108]|abstract	new[106]|new[108]|giv	coref	18-20[122_0]
16-15	1813-1814	.	_	_	_	_

#Text=As mentioned above , apelin is a powerful angiogenic agent through the activation of endothelial APJ and different downstream signalling pathways .
17-1	1815-1817	As	_	_	_	_
17-2	1818-1827	mentioned	_	_	_	_
17-3	1828-1833	above	_	_	_	_
17-4	1834-1835	,	_	_	_	_
17-5	1836-1842	apelin	person	giv	coref	17-7[111_0]
17-6	1843-1845	is	_	_	_	_
17-7	1846-1847	a	person[111]	giv[111]	coref	19-22[0_111]
17-8	1848-1856	powerful	person[111]	giv[111]	_	_
17-9	1857-1867	angiogenic	person[111]	giv[111]	_	_
17-10	1868-1873	agent	person[111]	giv[111]	_	_
17-11	1874-1881	through	person[111]	giv[111]	_	_
17-12	1882-1885	the	person[111]|abstract[112]	giv[111]|new[112]	coref	19-19[129_112]
17-13	1886-1896	activation	person[111]|abstract[112]	giv[111]|new[112]	_	_
17-14	1897-1899	of	person[111]|abstract[112]	giv[111]|new[112]	_	_
17-15	1900-1911	endothelial	person[111]|abstract[112]|abstract|abstract[114]	giv[111]|new[112]|new|giv[114]	coref|coref|coref|coref	18-8[0_114]|25-16|18-8[0_114]|25-16
17-16	1912-1915	APJ	person[111]|abstract[112]|abstract[114]	giv[111]|new[112]|giv[114]	_	_
17-17	1916-1919	and	person[111]|abstract[112]	giv[111]|new[112]	_	_
17-18	1920-1929	different	person[111]|abstract[112]	giv[111]|new[112]	_	_
17-19	1930-1940	downstream	person[111]|abstract[112]	giv[111]|new[112]	_	_
17-20	1941-1951	signalling	_	_	_	_
17-21	1952-1960	pathways	place	new	_	_
17-22	1961-1962	.	_	_	_	_

#Text=Two reports have associated the inhibition of APJ with a reduction in angiogenesis and with a concomitant drop in fibrosis in CH and fibrotic rats .
18-1	1963-1966	Two	abstract[116]	new[116]	_	_
18-2	1967-1974	reports	abstract[116]	new[116]	_	_
18-3	1975-1979	have	_	_	_	_
18-4	1980-1990	associated	_	_	_	_
18-5	1991-1994	the	abstract[117]	giv[117]	_	_
18-6	1995-2005	inhibition	abstract[117]	giv[117]	_	_
18-7	2006-2008	of	abstract[117]	giv[117]	_	_
18-8	2009-2012	APJ	abstract[117]|abstract	giv[117]|giv	coref	19-19
18-9	2013-2017	with	_	_	_	_
18-10	2018-2019	a	abstract[119]	new[119]	_	_
18-11	2020-2029	reduction	abstract[119]	new[119]	_	_
18-12	2030-2032	in	abstract[119]	new[119]	_	_
18-13	2033-2045	angiogenesis	abstract[119]|abstract	new[119]|giv	coref	19-40[136_0]
18-14	2046-2049	and	_	_	_	_
18-15	2050-2054	with	_	_	_	_
18-16	2055-2056	a	object[121]	new[121]	_	_
18-17	2057-2068	concomitant	object[121]	new[121]	_	_
18-18	2069-2073	drop	object[121]	new[121]	_	_
18-19	2074-2076	in	object[121]	new[121]	_	_
18-20	2077-2085	fibrosis	object[121]|abstract[122]	new[121]|giv[122]	coref	21-16[154_122]
18-21	2086-2088	in	object[121]|abstract[122]	new[121]|giv[122]	_	_
18-22	2089-2091	CH	object[121]|abstract[122]|person|animal[124]	new[121]|giv[122]|new|giv[124]	coref|coref	30-23[257_124]|30-23[257_124]
18-23	2092-2095	and	object[121]|abstract[122]|animal[124]	new[121]|giv[122]|giv[124]	_	_
18-24	2096-2104	fibrotic	object[121]|abstract[122]|animal[124]	new[121]|giv[122]|giv[124]	_	_
18-25	2105-2109	rats	object[121]|abstract[122]|animal[124]	new[121]|giv[122]|giv[124]	_	_
18-26	2110-2111	.	_	_	_	_

#Text=Although a direct relationship was not established between the two phenomena , there are evidence pointing out that APJ activation by apelin stimulates the expression of a well-known pro-angiogenic factor , angiopoietin-1 ( from the angiopoietin family involved in pathological angiogenesis in chronic liver disease ) in LX-2 cells .
19-1	2112-2120	Although	_	_	_	_
19-2	2121-2122	a	abstract[125]	giv[125]	_	_
19-3	2123-2129	direct	abstract[125]	giv[125]	_	_
19-4	2130-2142	relationship	abstract[125]	giv[125]	_	_
19-5	2143-2146	was	_	_	_	_
19-6	2147-2150	not	_	_	_	_
19-7	2151-2162	established	_	_	_	_
19-8	2163-2170	between	_	_	_	_
19-9	2171-2174	the	abstract[126]	new[126]	coref	22-13[160_126]
19-10	2175-2178	two	abstract[126]	new[126]	_	_
19-11	2179-2188	phenomena	abstract[126]	new[126]	_	_
19-12	2189-2190	,	_	_	_	_
19-13	2191-2196	there	_	_	_	_
19-14	2197-2200	are	_	_	_	_
19-15	2201-2209	evidence	abstract	new	_	_
19-16	2210-2218	pointing	_	_	_	_
19-17	2219-2222	out	_	_	_	_
19-18	2223-2227	that	_	_	_	_
19-19	2228-2231	APJ	abstract|event[129]	giv|giv[129]	coref|coref	26-8|26-8
19-20	2232-2242	activation	event[129]	giv[129]	_	_
19-21	2243-2245	by	event[129]	giv[129]	_	_
19-22	2246-2252	apelin	event[129]|organization	giv[129]|giv	coref	29-29[244_0]
19-23	2253-2263	stimulates	_	_	_	_
19-24	2264-2267	the	event[131]	new[131]	ana	20-1[0_131]
19-25	2268-2278	expression	event[131]	new[131]	_	_
19-26	2279-2281	of	event[131]	new[131]	_	_
19-27	2282-2283	a	event[131]|abstract[132]	new[131]|new[132]	appos	19-32[133_132]
19-28	2284-2294	well-known	event[131]|abstract[132]	new[131]|new[132]	_	_
19-29	2295-2309	pro-angiogenic	event[131]|abstract[132]	new[131]|new[132]	_	_
19-30	2310-2316	factor	event[131]|abstract[132]	new[131]|new[132]	_	_
19-31	2317-2318	,	_	_	_	_
19-32	2319-2333	angiopoietin-1	abstract[133]	giv[133]	coref	25-15[204_133]
19-33	2334-2335	(	abstract[133]	giv[133]	_	_
19-34	2336-2340	from	abstract[133]	giv[133]	_	_
19-35	2341-2344	the	abstract[133]|abstract[135]	giv[133]|new[135]	_	_
19-36	2345-2357	angiopoietin	abstract[133]|abstract|abstract[135]	giv[133]|new|new[135]	coref	20-20[148_0]
19-37	2358-2364	family	abstract[133]|abstract[135]	giv[133]|new[135]	_	_
19-38	2365-2373	involved	_	_	_	_
19-39	2374-2376	in	_	_	_	_
19-40	2377-2389	pathological	abstract[136]	giv[136]	coref	20-12[145_136]
19-41	2390-2402	angiogenesis	abstract[136]	giv[136]	_	_
19-42	2403-2405	in	abstract[136]	giv[136]	_	_
19-43	2406-2413	chronic	abstract[136]|abstract[138]	giv[136]|giv[138]	coref	24-13[182_138]
19-44	2414-2419	liver	abstract[136]|object|abstract[138]	giv[136]|giv|giv[138]	coref	21-16
19-45	2420-2427	disease	abstract[136]|abstract[138]	giv[136]|giv[138]	_	_
19-46	2428-2429	)	_	_	_	_
19-47	2430-2432	in	_	_	_	_
19-48	2433-2437	LX-2	substance|object[140]	giv|giv[140]	coref|coref|coref|coref	20-4[142_140]|26-10|20-4[142_140]|26-10
19-49	2438-2443	cells	object[140]	giv[140]	_	_
19-50	2444-2445	.	_	_	_	_

#Text=This suggests that fibrogenic cells such as HSC may participate in hepatic angiogenesis by secreting angiogenic factors such as angiopoietin 1 .
20-1	2446-2450	This	event	giv	_	_
20-2	2451-2459	suggests	_	_	_	_
20-3	2460-2464	that	_	_	_	_
20-4	2465-2475	fibrogenic	object[142]	giv[142]	coref	23-31[176_142]
20-5	2476-2481	cells	object[142]	giv[142]	_	_
20-6	2482-2486	such	object[142]	giv[142]	_	_
20-7	2487-2489	as	object[142]	giv[142]	_	_
20-8	2490-2493	HSC	object[142]|substance	giv[142]|giv	coref	22-3
20-9	2494-2497	may	_	_	_	_
20-10	2498-2509	participate	_	_	_	_
20-11	2510-2512	in	_	_	_	_
20-12	2513-2520	hepatic	abstract|abstract[145]	new|giv[145]	coref|coref|coref|coref	21-13[151_145]|23-32|21-13[151_145]|23-32
20-13	2521-2533	angiogenesis	abstract[145]	giv[145]	_	_
20-14	2534-2536	by	_	_	_	_
20-15	2537-2546	secreting	_	_	_	_
20-16	2547-2557	angiogenic	abstract|abstract[147]	new|new[147]	coref|coref	22-24[164_147]|22-24[164_147]
20-17	2558-2565	factors	abstract[147]	new[147]	_	_
20-18	2566-2570	such	abstract[147]	new[147]	_	_
20-19	2571-2573	as	abstract[147]	new[147]	_	_
20-20	2574-2586	angiopoietin	abstract[147]|abstract[148]	new[147]|giv[148]	_	_
20-21	2587-2588	1	abstract[147]|abstract[148]	new[147]|giv[148]	_	_
20-22	2589-2590	.	_	_	_	_

#Text=Indeed , the inhibition of HSC-secreted angiopietin-1 has shown to drastically reduce pathological angiogenesis and liver fibrosis induced in mice by either CCl4 or BDL .
21-1	2591-2597	Indeed	_	_	_	_
21-2	2598-2599	,	_	_	_	_
21-3	2600-2603	the	abstract[149]	new[149]	_	_
21-4	2604-2614	inhibition	abstract[149]	new[149]	_	_
21-5	2615-2617	of	abstract[149]	new[149]	_	_
21-6	2618-2630	HSC-secreted	abstract[149]|abstract[150]	new[149]|new[150]	_	_
21-7	2631-2644	angiopietin-1	abstract[149]|abstract[150]	new[149]|new[150]	_	_
21-8	2645-2648	has	_	_	_	_
21-9	2649-2654	shown	_	_	_	_
21-10	2655-2657	to	_	_	_	_
21-11	2658-2669	drastically	_	_	_	_
21-12	2670-2676	reduce	_	_	_	_
21-13	2677-2689	pathological	abstract[151]|abstract[152]	giv[151]|giv[152]	coref|coref|coref|coref	22-16[161_151]|23-13[169_152]|22-16[161_151]|23-13[169_152]
21-14	2690-2702	angiogenesis	abstract[151]|abstract[152]	giv[151]|giv[152]	_	_
21-15	2703-2706	and	abstract[152]	giv[152]	_	_
21-16	2707-2712	liver	abstract[152]|object|abstract[154]	giv[152]|giv|giv[154]	coref|coref|coref|coref	22-19|22-19[163_154]|22-19|22-19[163_154]
21-17	2713-2721	fibrosis	abstract[152]|abstract[154]	giv[152]|giv[154]	_	_
21-18	2722-2729	induced	_	_	_	_
21-19	2730-2732	in	_	_	_	_
21-20	2733-2737	mice	animal	new	_	_
21-21	2738-2740	by	_	_	_	_
21-22	2741-2747	either	object[156]	giv[156]	_	_
21-23	2748-2752	CCl4	object[156]	giv[156]	_	_
21-24	2753-2755	or	_	_	_	_
21-25	2756-2759	BDL	abstract	new	_	_
21-26	2760-2761	.	_	_	_	_

#Text=Aside from HSC , hepatocytes have also been related to contribute to both phenomena , pathological angiogenesis and liver fibrosis , by releasing pro-angiogenic and pro-fibrogenic factors .
22-1	2762-2767	Aside	_	_	_	_
22-2	2768-2772	from	_	_	_	_
22-3	2773-2776	HSC	abstract	giv	coref	23-27
22-4	2777-2778	,	_	_	_	_
22-5	2779-2790	hepatocytes	abstract	new	coref	23-29
22-6	2791-2795	have	_	_	_	_
22-7	2796-2800	also	_	_	_	_
22-8	2801-2805	been	_	_	_	_
22-9	2806-2813	related	_	_	_	_
22-10	2814-2816	to	_	_	_	_
22-11	2817-2827	contribute	_	_	_	_
22-12	2828-2830	to	_	_	_	_
22-13	2831-2835	both	abstract[160]	giv[160]	_	_
22-14	2836-2845	phenomena	abstract[160]	giv[160]	_	_
22-15	2846-2847	,	_	_	_	_
22-16	2848-2860	pathological	abstract[161]	giv[161]	coref	23-13[168_161]
22-17	2861-2873	angiogenesis	abstract[161]	giv[161]	_	_
22-18	2874-2877	and	_	_	_	_
22-19	2878-2883	liver	object|abstract[163]	giv|giv[163]	coref|coref|coref|coref	23-17|28-27[235_163]|23-17|28-27[235_163]
22-20	2884-2892	fibrosis	abstract[163]	giv[163]	_	_
22-21	2893-2894	,	_	_	_	_
22-22	2895-2897	by	_	_	_	_
22-23	2898-2907	releasing	_	_	_	_
22-24	2908-2922	pro-angiogenic	abstract[164]	giv[164]	coref	24-33[187_164]
22-25	2923-2926	and	abstract[164]	giv[164]	_	_
22-26	2927-2941	pro-fibrogenic	abstract[164]	giv[164]	_	_
22-27	2942-2949	factors	abstract[164]	giv[164]	_	_
22-28	2950-2951	.	_	_	_	_

#Text=There is a growing belief that local hypoxia is the link interconnecting both pathological angiogenesis and liver fibrogenesis , orchestrating the harmonic and coordinated activation of HSC , hepatocytes and other hepatic cells .
23-1	2952-2957	There	_	_	_	_
23-2	2958-2960	is	_	_	_	_
23-3	2961-2962	a	abstract[165]	new[165]	_	_
23-4	2963-2970	growing	abstract[165]	new[165]	_	_
23-5	2971-2977	belief	abstract[165]	new[165]	_	_
23-6	2978-2982	that	_	_	_	_
23-7	2983-2988	local	abstract[166]	new[166]	coref	23-10[167_166]
23-8	2989-2996	hypoxia	abstract[166]	new[166]	_	_
23-9	2997-2999	is	_	_	_	_
23-10	3000-3003	the	abstract[167]	giv[167]	coref	24-39[190_167]
23-11	3004-3008	link	abstract[167]	giv[167]	_	_
23-12	3009-3024	interconnecting	_	_	_	_
23-13	3025-3029	both	abstract[168]|abstract[169]	giv[168]|giv[169]	coref|coref	24-57[0_168]|24-57[0_168]
23-14	3030-3042	pathological	abstract[168]|abstract[169]	giv[168]|giv[169]	_	_
23-15	3043-3055	angiogenesis	abstract[168]|abstract[169]	giv[168]|giv[169]	_	_
23-16	3056-3059	and	abstract[169]	giv[169]	_	_
23-17	3060-3065	liver	abstract[169]|object|object[171]	giv[169]|giv|new[171]	coref|coref	24-14|24-14
23-18	3066-3078	fibrogenesis	abstract[169]|object[171]	giv[169]|new[171]	_	_
23-19	3079-3080	,	_	_	_	_
23-20	3081-3094	orchestrating	_	_	_	_
23-21	3095-3098	the	abstract[172]	new[172]	coref	28-1[224_172]
23-22	3099-3107	harmonic	abstract[172]	new[172]	_	_
23-23	3108-3111	and	abstract[172]	new[172]	_	_
23-24	3112-3123	coordinated	abstract[172]	new[172]	_	_
23-25	3124-3134	activation	abstract[172]	new[172]	_	_
23-26	3135-3137	of	abstract[172]	new[172]	_	_
23-27	3138-3141	HSC	abstract[172]|abstract	new[172]|giv	coref	26-12
23-28	3142-3143	,	abstract[172]	new[172]	_	_
23-29	3144-3155	hepatocytes	abstract[172]|object	new[172]|giv	_	_
23-30	3156-3159	and	abstract[172]	new[172]	_	_
23-31	3160-3165	other	abstract[172]|object[176]	new[172]|giv[176]	coref	27-18[222_176]
23-32	3166-3173	hepatic	abstract[172]|substance|object[176]	new[172]|giv|giv[176]	coref	24-39
23-33	3174-3179	cells	abstract[172]|object[176]	new[172]|giv[176]	_	_
23-34	3180-3181	.	_	_	_	_

#Text=Detection of hypoxic areas is a common trait at any stage of chronic liver disease , expanding progressively from early injury to the development of cirrhosis . , Through the action of hypoxia-inducible factors ( HIF ) , hepatic hypoxia up-regulates the expression of a wide array of growth factors and mediators of liver repair and angiogenesis .
24-1	3182-3191	Detection	abstract[177]	new[177]	coref	24-6[179_177]
24-2	3192-3194	of	abstract[177]	new[177]	_	_
24-3	3195-3202	hypoxic	abstract[177]|place[178]	new[177]|new[178]	_	_
24-4	3203-3208	areas	abstract[177]|place[178]	new[177]|new[178]	_	_
24-5	3209-3211	is	_	_	_	_
24-6	3212-3213	a	abstract[179]	giv[179]	_	_
24-7	3214-3220	common	abstract[179]	giv[179]	_	_
24-8	3221-3226	trait	abstract[179]	giv[179]	_	_
24-9	3227-3229	at	abstract[179]	giv[179]	_	_
24-10	3230-3233	any	abstract[179]|abstract[180]	giv[179]|new[180]	_	_
24-11	3234-3239	stage	abstract[179]|abstract[180]	giv[179]|new[180]	_	_
24-12	3240-3242	of	abstract[179]|abstract[180]	giv[179]|new[180]	_	_
24-13	3243-3250	chronic	abstract[179]|abstract[180]|abstract[182]	giv[179]|new[180]|giv[182]	coref	31-12[270_182]
24-14	3251-3256	liver	abstract[179]|abstract[180]|object|abstract[182]	giv[179]|new[180]|giv|giv[182]	coref	24-54
24-15	3257-3264	disease	abstract[179]|abstract[180]|abstract[182]	giv[179]|new[180]|giv[182]	_	_
24-16	3265-3266	,	_	_	_	_
24-17	3267-3276	expanding	_	_	_	_
24-18	3277-3290	progressively	_	_	_	_
24-19	3291-3295	from	_	_	_	_
24-20	3296-3301	early	event[183]	new[183]	coref	29-40[0_183]
24-21	3302-3308	injury	event[183]	new[183]	_	_
24-22	3309-3311	to	_	_	_	_
24-23	3312-3315	the	event[184]	new[184]	_	_
24-24	3316-3327	development	event[184]	new[184]	_	_
24-25	3328-3330	of	event[184]	new[184]	_	_
24-26	3331-3340	cirrhosis	event[184]|abstract	new[184]|new	coref	30-29[260_0]
24-27	3341-3342	.	_	_	_	_
24-28	3343-3344	,	_	_	_	_
24-29	3345-3352	Through	_	_	_	_
24-30	3353-3356	the	abstract[186]	new[186]	_	_
24-31	3357-3363	action	abstract[186]	new[186]	_	_
24-32	3364-3366	of	abstract[186]	new[186]	_	_
24-33	3367-3384	hypoxia-inducible	abstract[186]|abstract[187]	new[186]|giv[187]	appos	24-36[0_187]
24-34	3385-3392	factors	abstract[186]|abstract[187]	new[186]|giv[187]	_	_
24-35	3393-3394	(	abstract[186]	new[186]	_	_
24-36	3395-3398	HIF	abstract[186]|abstract	new[186]|giv	coref	24-49[194_0]
24-37	3399-3400	)	abstract[186]	new[186]	_	_
24-38	3401-3402	,	abstract[186]	new[186]	_	_
24-39	3403-3410	hepatic	abstract[186]|person|abstract[190]|abstract[191]	new[186]|giv|giv[190]|new[191]	coref|coref|coref|coref|coref|coref	25-34[0_190]|26-1[209_191]|25-34[0_190]|26-1[209_191]|25-34[0_190]|26-1[209_191]
24-40	3411-3418	hypoxia	abstract[186]|abstract[190]|abstract[191]	new[186]|giv[190]|new[191]	_	_
24-41	3419-3431	up-regulates	abstract[186]|abstract[191]	new[186]|new[191]	_	_
24-42	3432-3435	the	abstract[186]|abstract[191]|abstract[192]	new[186]|new[191]|new[192]	_	_
24-43	3436-3446	expression	abstract[186]|abstract[191]|abstract[192]	new[186]|new[191]|new[192]	_	_
24-44	3447-3449	of	abstract[186]|abstract[191]|abstract[192]	new[186]|new[191]|new[192]	_	_
24-45	3450-3451	a	abstract[186]|abstract[191]|abstract[192]|place[193]	new[186]|new[191]|new[192]|new[193]	_	_
24-46	3452-3456	wide	abstract[186]|abstract[191]|abstract[192]|place[193]	new[186]|new[191]|new[192]|new[193]	_	_
24-47	3457-3462	array	abstract[186]|abstract[191]|abstract[192]|place[193]	new[186]|new[191]|new[192]|new[193]	_	_
24-48	3463-3465	of	abstract[186]|abstract[191]|abstract[192]|place[193]	new[186]|new[191]|new[192]|new[193]	_	_
24-49	3466-3472	growth	abstract[186]|abstract[191]|abstract[192]|place[193]|abstract[194]	new[186]|new[191]|new[192]|new[193]|giv[194]	coref	28-14[0_194]
24-50	3473-3480	factors	abstract[186]|abstract[191]|abstract[192]|place[193]|abstract[194]	new[186]|new[191]|new[192]|new[193]|giv[194]	_	_
24-51	3481-3484	and	abstract[186]|abstract[191]|abstract[192]|place[193]|abstract[194]	new[186]|new[191]|new[192]|new[193]|giv[194]	_	_
24-52	3485-3494	mediators	abstract[186]|abstract[191]|abstract[192]|place[193]|abstract[194]|person[195]	new[186]|new[191]|new[192]|new[193]|giv[194]|new[195]	_	_
24-53	3495-3497	of	abstract[186]|abstract[191]|abstract[192]|place[193]|abstract[194]|person[195]	new[186]|new[191]|new[192]|new[193]|giv[194]|new[195]	_	_
24-54	3498-3503	liver	abstract[186]|abstract[191]|abstract[192]|place[193]|abstract[194]|person[195]|object|abstract[197]	new[186]|new[191]|new[192]|new[193]|giv[194]|new[195]|giv|new[197]	coref|coref	25-27[206_0]|25-27[206_0]
24-55	3504-3510	repair	abstract[186]|abstract[191]|abstract[192]|place[193]|abstract[194]|person[195]|abstract[197]	new[186]|new[191]|new[192]|new[193]|giv[194]|new[195]|new[197]	_	_
24-56	3511-3514	and	abstract[186]|abstract[191]|abstract[192]|place[193]|abstract[194]|person[195]	new[186]|new[191]|new[192]|new[193]|giv[194]|new[195]	_	_
24-57	3515-3527	angiogenesis	abstract[186]|abstract[191]|abstract[192]|place[193]|abstract[194]|person[195]|abstract	new[186]|new[191]|new[192]|new[193]|giv[194]|new[195]|giv	coref	25-3[199_0]
24-58	3528-3529	.	_	_	_	_

#Text=However , pathological angiogenesis can be inefficient due to the immaturity and permeability of vascular endothelial growth factor ( VEGF)-induced new vessels and , consequently , the liver may be unable to reduce hypoxia .
25-1	3530-3537	However	_	_	_	_
25-2	3538-3539	,	_	_	_	_
25-3	3540-3552	pathological	abstract[199]	giv[199]	coref	28-20[0_199]
25-4	3553-3565	angiogenesis	abstract[199]	giv[199]	_	_
25-5	3566-3569	can	_	_	_	_
25-6	3570-3572	be	_	_	_	_
25-7	3573-3584	inefficient	_	_	_	_
25-8	3585-3588	due	_	_	_	_
25-9	3589-3591	to	_	_	_	_
25-10	3592-3595	the	abstract[200]	new[200]	_	_
25-11	3596-3606	immaturity	abstract[200]	new[200]	_	_
25-12	3607-3610	and	_	_	_	_
25-13	3611-3623	permeability	abstract[201]	new[201]	_	_
25-14	3624-3626	of	abstract[201]	new[201]	_	_
25-15	3627-3635	vascular	abstract[201]|abstract[204]	new[201]|giv[204]	_	_
25-16	3636-3647	endothelial	abstract[201]|abstract|abstract[204]	new[201]|giv|giv[204]	_	_
25-17	3648-3654	growth	abstract[201]|abstract|abstract[204]	new[201]|new|giv[204]	_	_
25-18	3655-3661	factor	abstract[201]|abstract[204]	new[201]|giv[204]	_	_
25-19	3662-3663	(	_	_	_	_
25-20	3664-3677	VEGF)-induced	object[205]	new[205]	_	_
25-21	3678-3681	new	object[205]	new[205]	_	_
25-22	3682-3689	vessels	object[205]	new[205]	_	_
25-23	3690-3693	and	_	_	_	_
25-24	3694-3695	,	_	_	_	_
25-25	3696-3708	consequently	_	_	_	_
25-26	3709-3710	,	_	_	_	_
25-27	3711-3714	the	object[206]	giv[206]	coref	28-29[0_206]
25-28	3715-3720	liver	object[206]	giv[206]	_	_
25-29	3721-3724	may	_	_	_	_
25-30	3725-3727	be	_	_	_	_
25-31	3728-3734	unable	_	_	_	_
25-32	3735-3737	to	_	_	_	_
25-33	3738-3744	reduce	_	_	_	_
25-34	3745-3752	hypoxia	abstract	giv	coref	26-1
25-35	3753-3754	.	_	_	_	_

#Text=Hypoxia up-regulates in vitro the expression of APJ in LX-2 ( HSC ) and in HepG2 ( hepatocytes ) .
26-1	3755-3762	Hypoxia	abstract|abstract[209]	giv|giv[209]	coref|coref	29-6|29-6
26-2	3763-3775	up-regulates	abstract[209]	giv[209]	_	_
26-3	3776-3778	in	abstract[209]	giv[209]	_	_
26-4	3779-3784	vitro	abstract[209]	giv[209]	_	_
26-5	3785-3788	the	abstract[209]|abstract[210]	giv[209]|new[210]	_	_
26-6	3789-3799	expression	abstract[209]|abstract[210]	giv[209]|new[210]	_	_
26-7	3800-3802	of	abstract[209]|abstract[210]	giv[209]|new[210]	_	_
26-8	3803-3806	APJ	abstract[209]|abstract[210]|abstract	giv[209]|new[210]|giv	coref	27-16
26-9	3807-3809	in	abstract[209]|abstract[210]	giv[209]|new[210]	_	_
26-10	3810-3814	LX-2	abstract[209]|abstract[210]|abstract	giv[209]|new[210]|giv	_	_
26-11	3815-3816	(	_	_	_	_
26-12	3817-3820	HSC	place	giv	coref	28-24
26-13	3821-3822	)	_	_	_	_
26-14	3823-3826	and	_	_	_	_
26-15	3827-3829	in	_	_	_	_
26-16	3830-3835	HepG2	object	new	appos	26-18
26-17	3836-3837	(	_	_	_	_
26-18	3838-3849	hepatocytes	object	giv	coref	27-18
26-19	3850-3851	)	_	_	_	_
26-20	3852-3853	.	_	_	_	_

#Text=Interestingly , the pro-inflammatory and pro-fibrogenic agents TNF-Î± and AII also induce the expression of APJ in HepG2 cells .
27-1	3854-3867	Interestingly	_	_	_	_
27-2	3868-3869	,	_	_	_	_
27-3	3870-3873	the	person[216]|abstract[217]	new[216]|new[217]	_	_
27-4	3874-3890	pro-inflammatory	person[216]|abstract[217]	new[216]|new[217]	_	_
27-5	3891-3894	and	person[216]|abstract[217]	new[216]|new[217]	_	_
27-6	3895-3909	pro-fibrogenic	person[216]|abstract[217]	new[216]|new[217]	_	_
27-7	3910-3916	agents	person[216]|abstract[217]	new[216]|new[217]	_	_
27-8	3917-3922	TNF-Î±	abstract[217]	new[217]	_	_
27-9	3923-3926	and	_	_	_	_
27-10	3927-3930	AII	event	giv	_	_
27-11	3931-3935	also	_	_	_	_
27-12	3936-3942	induce	_	_	_	_
27-13	3943-3946	the	abstract[219]	new[219]	_	_
27-14	3947-3957	expression	abstract[219]	new[219]	_	_
27-15	3958-3960	of	abstract[219]	new[219]	_	_
27-16	3961-3964	APJ	abstract[219]|abstract	new[219]|giv	coref	28-1
27-17	3965-3967	in	abstract[219]	new[219]	_	_
27-18	3968-3973	HepG2	abstract[219]|substance|object[222]	new[219]|giv|giv[222]	coref|coref|coref|coref	28-4|28-4[226_222]|28-4|28-4[226_222]
27-19	3974-3979	cells	abstract[219]|object[222]	new[219]|giv[222]	_	_
27-20	3980-3981	.	_	_	_	_

#Text=APJ activation in HepG2 cells triggers the expression of VEGF-A and PDGF-Î² , factors that in turn may promote angiogenesis and activation of HSC and , consequently , liver fibrosis .
28-1	3982-3985	APJ	abstract|event[224]	giv|giv[224]	coref|coref	29-12[240_0]|29-12[240_0]
28-2	3986-3996	activation	event[224]	giv[224]	_	_
28-3	3997-3999	in	event[224]	giv[224]	_	_
28-4	4000-4005	HepG2	event[224]|substance|object[226]	giv[224]|giv|giv[226]	coref|coref	29-17|29-17
28-5	4006-4011	cells	event[224]|object[226]	giv[224]|giv[226]	_	_
28-6	4012-4020	triggers	_	_	_	_
28-7	4021-4024	the	abstract[227]	new[227]	_	_
28-8	4025-4035	expression	abstract[227]	new[227]	_	_
28-9	4036-4038	of	abstract[227]	new[227]	_	_
28-10	4039-4045	VEGF-A	abstract[227]|abstract	new[227]|new	_	_
28-11	4046-4049	and	abstract[227]	new[227]	_	_
28-12	4050-4056	PDGF-Î²	abstract[227]|abstract	new[227]|giv	_	_
28-13	4057-4058	,	abstract[227]	new[227]	_	_
28-14	4059-4066	factors	abstract[227]|abstract	new[227]|giv	coref	29-10[239_0]
28-15	4067-4071	that	_	_	_	_
28-16	4072-4074	in	_	_	_	_
28-17	4075-4079	turn	_	_	_	_
28-18	4080-4083	may	_	_	_	_
28-19	4084-4091	promote	_	_	_	_
28-20	4092-4104	angiogenesis	abstract	giv	_	_
28-21	4105-4108	and	_	_	_	_
28-22	4109-4119	activation	event[232]	new[232]	_	_
28-23	4120-4122	of	event[232]	new[232]	_	_
28-24	4123-4126	HSC	event[232]|abstract	new[232]|giv	coref	29-15
28-25	4127-4130	and	_	_	_	_
28-26	4131-4132	,	_	_	_	_
28-27	4133-4145	consequently	abstract[235]	giv[235]	coref	29-38[0_235]
28-28	4146-4147	,	abstract[235]	giv[235]	_	_
28-29	4148-4153	liver	object|abstract[235]	giv|giv[235]	coref	30-29
28-30	4154-4162	fibrosis	abstract[235]	giv[235]	_	_
28-31	4163-4164	.	_	_	_	_

#Text=According to these data , hypoxia , inflammation and pro-fibrogenic factors up-regulate APJ in HSC and hepatocytes , which can release different pro-angiogenic and pro-fibrogenic factors such as apelin ( from activated HSC ) together to perpetuate fibrosis while injury and these stimuli remain .
29-1	4165-4174	According	_	_	_	_
29-2	4175-4177	to	_	_	_	_
29-3	4178-4183	these	abstract[236]	giv[236]	_	_
29-4	4184-4188	data	abstract[236]	giv[236]	_	_
29-5	4189-4190	,	abstract[236]	giv[236]	_	_
29-6	4191-4198	hypoxia	abstract[236]|abstract	giv[236]|giv	_	_
29-7	4199-4200	,	abstract[236]	giv[236]	_	_
29-8	4201-4213	inflammation	abstract[236]|abstract	giv[236]|new	_	_
29-9	4214-4217	and	abstract[236]	giv[236]	_	_
29-10	4218-4232	pro-fibrogenic	abstract[236]|abstract[239]	giv[236]|giv[239]	coref	29-22[243_239]
29-11	4233-4240	factors	abstract[236]|abstract[239]	giv[236]|giv[239]	_	_
29-12	4241-4252	up-regulate	abstract[236]|abstract[240]	giv[236]|giv[240]	coref	30-4[0_240]
29-13	4253-4256	APJ	abstract[236]|abstract[240]	giv[236]|giv[240]	_	_
29-14	4257-4259	in	abstract[236]|abstract[240]	giv[236]|giv[240]	_	_
29-15	4260-4263	HSC	abstract[236]|abstract[240]|place	giv[236]|giv[240]|giv	coref	29-33
29-16	4264-4267	and	abstract[236]|abstract[240]	giv[236]|giv[240]	_	_
29-17	4268-4279	hepatocytes	abstract[236]|abstract[240]|abstract	giv[236]|giv[240]|giv	coref	30-9[251_0]
29-18	4280-4281	,	_	_	_	_
29-19	4282-4287	which	_	_	_	_
29-20	4288-4291	can	_	_	_	_
29-21	4292-4299	release	_	_	_	_
29-22	4300-4309	different	abstract[243]	giv[243]	_	_
29-23	4310-4324	pro-angiogenic	abstract[243]	giv[243]	_	_
29-24	4325-4328	and	abstract[243]	giv[243]	_	_
29-25	4329-4343	pro-fibrogenic	abstract[243]	giv[243]	_	_
29-26	4344-4351	factors	abstract[243]	giv[243]	_	_
29-27	4352-4356	such	abstract[243]	giv[243]	_	_
29-28	4357-4359	as	abstract[243]	giv[243]	_	_
29-29	4360-4366	apelin	abstract[243]|organization[244]	giv[243]|giv[244]	coref	30-14[0_244]
29-30	4367-4368	(	abstract[243]|organization[244]	giv[243]|giv[244]	_	_
29-31	4369-4373	from	abstract[243]|organization[244]	giv[243]|giv[244]	_	_
29-32	4374-4383	activated	abstract[243]|organization[244]	giv[243]|giv[244]	_	_
29-33	4384-4387	HSC	abstract[243]|organization[244]|substance	giv[243]|giv[244]|giv	coref	30-11
29-34	4388-4389	)	abstract[243]|organization[244]	giv[243]|giv[244]	_	_
29-35	4390-4398	together	_	_	_	_
29-36	4399-4401	to	_	_	_	_
29-37	4402-4412	perpetuate	_	_	_	_
29-38	4413-4421	fibrosis	abstract	giv	coref	32-37[282_0]
29-39	4422-4427	while	_	_	_	_
29-40	4428-4434	injury	event	giv	_	_
29-41	4435-4438	and	_	_	_	_
29-42	4439-4444	these	abstract[248]	new[248]	_	_
29-43	4445-4452	stimuli	abstract[248]	new[248]	_	_
29-44	4453-4459	remain	_	_	_	_
29-45	4460-4461	.	_	_	_	_

#Text=In vivo , APJ is upregulated preferentially in hepatocytes and HSC , while apelin levels are increased and localized in HSC in cirrhotic rats and in patients with liver cirrhosis caused by hepatitis C virus or ethanol .
30-1	4462-4464	In	_	_	_	_
30-2	4465-4469	vivo	abstract	new	_	_
30-3	4470-4471	,	_	_	_	_
30-4	4472-4475	APJ	abstract	giv	_	_
30-5	4476-4478	is	_	_	_	_
30-6	4479-4490	upregulated	_	_	_	_
30-7	4491-4505	preferentially	_	_	_	_
30-8	4506-4508	in	_	_	_	_
30-9	4509-4520	hepatocytes	abstract[251]	giv[251]	_	_
30-10	4521-4524	and	abstract[251]	giv[251]	_	_
30-11	4525-4528	HSC	abstract[251]|substance	giv[251]|giv	coref	30-21[255_0]
30-12	4529-4530	,	_	_	_	_
30-13	4531-4536	while	_	_	_	_
30-14	4537-4543	apelin	organization|abstract[254]	giv|new[254]	coref|coref|coref|coref	31-2|31-1[266_254]|31-2|31-1[266_254]
30-15	4544-4550	levels	abstract[254]	new[254]	_	_
30-16	4551-4554	are	_	_	_	_
30-17	4555-4564	increased	_	_	_	_
30-18	4565-4568	and	_	_	_	_
30-19	4569-4578	localized	_	_	_	_
30-20	4579-4581	in	_	_	_	_
30-21	4582-4585	HSC	substance[255]	giv[255]	_	_
30-22	4586-4588	in	substance[255]	giv[255]	_	_
30-23	4589-4598	cirrhotic	substance[255]|animal|animal[257]	giv[255]|new|giv[257]	_	_
30-24	4599-4603	rats	substance[255]|animal[257]	giv[255]|giv[257]	_	_
30-25	4604-4607	and	_	_	_	_
30-26	4608-4610	in	_	_	_	_
30-27	4611-4619	patients	person[258]	new[258]	_	_
30-28	4620-4624	with	person[258]	new[258]	_	_
30-29	4625-4630	liver	person[258]|object|abstract[260]	new[258]|giv|giv[260]	coref|coref	31-5|31-5
30-30	4631-4640	cirrhosis	person[258]|abstract[260]	new[258]|giv[260]	_	_
30-31	4641-4647	caused	_	_	_	_
30-32	4648-4650	by	_	_	_	_
30-33	4651-4660	hepatitis	abstract	new	appos	30-34[263_0]
30-34	4661-4662	C	person|abstract[263]	new|giv[263]	_	_
30-35	4663-4668	virus	abstract[263]	giv[263]	_	_
30-36	4669-4671	or	_	_	_	_
30-37	4672-4679	ethanol	substance	new	_	_
30-38	4680-4681	.	_	_	_	_

#Text=High apelin levels and liver damage have also been observed in human non-alcoholic fatty liver disease .
31-1	4682-4686	High	abstract[266]	giv[266]	coref	32-8[273_266]
31-2	4687-4693	apelin	organization|abstract[266]	giv|giv[266]	coref	32-8
31-3	4694-4700	levels	abstract[266]	giv[266]	_	_
31-4	4701-4704	and	abstract[266]	giv[266]	_	_
31-5	4705-4710	liver	abstract[266]|object|abstract[268]	giv[266]|giv|new[268]	coref|coref	31-15|31-15
31-6	4711-4717	damage	abstract[266]|abstract[268]	giv[266]|new[268]	_	_
31-7	4718-4722	have	_	_	_	_
31-8	4723-4727	also	_	_	_	_
31-9	4728-4732	been	_	_	_	_
31-10	4733-4741	observed	_	_	_	_
31-11	4742-4744	in	_	_	_	_
31-12	4745-4750	human	abstract[270]	giv[270]	coref	32-18[276_270]
31-13	4751-4764	non-alcoholic	abstract[270]	giv[270]	_	_
31-14	4765-4770	fatty	abstract[270]	giv[270]	_	_
31-15	4771-4776	liver	object|abstract[270]	giv|giv[270]	coref	32-19
31-16	4777-4784	disease	abstract[270]	giv[270]	_	_
31-17	4785-4786	.	_	_	_	_

#Text=A contemporary clinical investigation revealed that circulating apelin levels are associated with histological and hemodynamic features of chronic liver disease , but more clinical studies are needed to confirm the major relevance of apelin system in human liver fibrosis .
32-1	4787-4788	A	abstract[271]	new[271]	_	_
32-2	4789-4801	contemporary	abstract[271]	new[271]	_	_
32-3	4802-4810	clinical	abstract[271]	new[271]	_	_
32-4	4811-4824	investigation	abstract[271]	new[271]	_	_
32-5	4825-4833	revealed	_	_	_	_
32-6	4834-4838	that	_	_	_	_
32-7	4839-4850	circulating	_	_	_	_
32-8	4851-4857	apelin	organization|abstract[273]	giv|giv[273]	coref|coref	32-34|32-34
32-9	4858-4864	levels	abstract[273]	giv[273]	_	_
32-10	4865-4868	are	_	_	_	_
32-11	4869-4879	associated	_	_	_	_
32-12	4880-4884	with	_	_	_	_
32-13	4885-4897	histological	abstract[274]	new[274]	_	_
32-14	4898-4901	and	abstract[274]	new[274]	_	_
32-15	4902-4913	hemodynamic	abstract[274]	new[274]	_	_
32-16	4914-4922	features	abstract[274]	new[274]	_	_
32-17	4923-4925	of	abstract[274]	new[274]	_	_
32-18	4926-4933	chronic	abstract[274]|abstract[276]	new[274]|giv[276]	_	_
32-19	4934-4939	liver	abstract[274]|object|abstract[276]	new[274]|giv|giv[276]	coref	32-38
32-20	4940-4947	disease	abstract[274]|abstract[276]	new[274]|giv[276]	_	_
32-21	4948-4949	,	_	_	_	_
32-22	4950-4953	but	_	_	_	_
32-23	4954-4958	more	abstract[277]	new[277]	_	_
32-24	4959-4967	clinical	abstract[277]	new[277]	_	_
32-25	4968-4975	studies	abstract[277]	new[277]	_	_
32-26	4976-4979	are	_	_	_	_
32-27	4980-4986	needed	_	_	_	_
32-28	4987-4989	to	_	_	_	_
32-29	4990-4997	confirm	_	_	_	_
32-30	4998-5001	the	abstract[278]	new[278]	_	_
32-31	5002-5007	major	abstract[278]	new[278]	_	_
32-32	5008-5017	relevance	abstract[278]	new[278]	_	_
32-33	5018-5020	of	abstract[278]	new[278]	_	_
32-34	5021-5027	apelin	abstract[278]|organization|abstract[280]	new[278]|giv|new[280]	_	_
32-35	5028-5034	system	abstract[278]|abstract[280]	new[278]|new[280]	_	_
32-36	5035-5037	in	abstract[278]|abstract[280]	new[278]|new[280]	_	_
32-37	5038-5043	human	abstract[278]|abstract[280]|abstract[282]	new[278]|new[280]|giv[282]	_	_
32-38	5044-5049	liver	abstract[278]|abstract[280]|object|abstract[282]	new[278]|new[280]|giv|giv[282]	_	_
32-39	5050-5058	fibrosis	abstract[278]|abstract[280]|abstract[282]	new[278]|new[280]|giv[282]	_	_
32-40	5059-5060	.	_	_	_	_
